Halozyme, Baxter study of Hylenex shows positive results

By Ted A. Knutson

Washington, Feb. 8 - Halozyme Therapeutics, Inc. and Baxter Healthcare Corp. announced Wednesday the results of Infuse-LR, a clinical trial of subcutaneous (Sub-Q) infusion (hypodermoclysis) with Hylenex.

The use of Hylenex preceding Sub-Q infusion accelerated the flow rate by about four-fold versus the Sub-Q infusion with a placebo, while causing less edema and was preferred by both investigators for 92% of subjects and by 92% of study subjects.

Hylenex recombinant (hyaluronidase human injection) is indicated for use as an adjuvant to increase the absorption and dispersion of other injected drugs, for hypodermoclysis, and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.

Hylenex is a liquid injectable formulation that includes the active pharmaceutical ingredient recombinant human hyaluronidase (rHuPH20), which is approved by the Food and Drug Administration for use as a spreading agent to increase the absorption and dispersion of other injected drugs and for Sub-Q hydration. Subcutaneous hydration is the introduction of fluids under the skin to replace inadequate intake or excessive loss of water and electrolytes during illness or operation.

Halozyme is a San Diego-based drug company.

Deerfield, Ill.-based Baxter is a drug manufacturer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.